Medications for Febrile Neutropenia

6 results

  • Cefepime (cefepime)

    (Cefepime)
    Apotex Corp.
    Usage: Cefepime for Injection is indicated for treating moderate to severe pneumonia, febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin infections, and complicated intra-abdominal infections (with metronidazole). It should be used when infections are proven or suspected to be caused by susceptible bacteria.

  • Ciprofloxacin (ciprofloxacin)

    (Ciprofloxacin)
    Rebel Distributors Corp
    Usage: Ciprofloxacin Injection, USP is indicated for treating infections by susceptible strains in adults and children, including urinary tract, lower respiratory, skin, bone, and joint infections, complicated intra-abdominal infections, and acute sinusitis. It is also used for post-exposure prophylaxis of inhalational anthrax.

  • Ciprofloxacin (ciprofloxacin)

    (ciprofloxacin)
    Sagent Pharmaceuticals
    Usage: Ciprofloxacin Injection is indicated for adult patients to treat various infections, including skin and skin structure, bone and joint, complicated intra-abdominal, nosocomial pneumonia, febrile neutropenia, inhalational anthrax, plague, chronic bacterial prostatitis, lower respiratory tract, and urinary tract infections, alongside pediatric applications for certain conditions.

  • Neulasta

    (pegfilgrastim)
    Amgen Inc
    Usage: Neulasta is indicated to reduce the incidence of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy, and to enhance survival in patients exposed to myelosuppressive doses of radiation. It is not indicated for mobilizing peripheral blood progenitor cells for stem cell transplantation.

  • Nyvepria

    (pegfilgrastim-apgf)
    Pfizer Laboratories Div Pfizer Inc
    Usage: NYVEPRIA is indicated to reduce the risk of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer therapy. It is not intended for mobilizing peripheral blood progenitor cells for stem cell transplantation.

  • Rolvedon

    (eflapegrastim-xnst)
    Spectrum Pharmaceuticals, Inc.
    Usage: Rolvedon is indicated to reduce the incidence of febrile neutropenia in adult patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy. It is not intended for mobilizing peripheral blood progenitor cells for stem cell transplantation.